Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 802 across all filing types
Latest filing 2009-04-27 Regulatory Filings
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
Prodarsan® granted Orphan Drug designation from FDA
Regulatory Filings Classification · 96% confidence The document is a press release dated April 27, 2009, announcing that Pharming Group NV's product, Prodarsan®, received Orphan Drug designation from the FDA for treating Cockayne Syndrome. This type of announcement, detailing a specific regulatory event (FDA designation) and providing context about the drug and disease, is characteristic of a general regulatory announcement or press release that doesn't fit the more specific categories like 10-K, ER, or IR. Since it is a specific regulatory update that isn't a standard financial report, and it doesn't fit DIRS, DIV, or MANG, the most appropriate general category for miscellaneous regulatory news is RNS (Regulatory Filings). It is not an Earnings Release (ER), Interim Report (IR), or a formal Audit Report (AR).
2009-04-27 English
Pharming announces first quarter 2009 financial results
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive quarterly financial report for Pharming Group NV for the period ended March 31, 2009. It includes detailed financial statements, specifically the Consolidated Balance Sheet, Consolidated Income Statement, and Consolidated Statement of Cash Flow, along with management commentary on the financial results. Since it contains substantive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report (IR). Q1 2009
2009-04-17 English
PHARMING ANNUAL SHAREHOLDER’S MEETING
AGM Information Classification · 99% confidence The document is explicitly titled 'PHARMING ANNUAL SHAREHOLDER'S MEETING' and discusses updates provided during the 'Annual Meeting of Shareholders (AGM) today'. It details strategic confirmations, product pipeline updates (Rhucin, Prodarsan), financing activities (standby equity agreement), and voting results on remuneration policy, board appointments, and auditor selection. Since the content is directly related to the proceedings and materials presented at the AGM, the most appropriate classification is AGM Information (AGM-R). Although it mentions voting results and management changes, the context is the meeting itself.
2009-04-16 English
Pharming secures € 20 million long term Standy Equity Agreement with Yorkville Advisors
Capital/Financing Update Classification · 99% confidence The document is a press release dated April 15, 2009, announcing that Pharming Group NV has entered into a Standby Equity Distribution Agreement (SEDA) with Yorkville Advisors for up to €20 million. This agreement details a financing mechanism involving the issuance of new shares over time. This clearly falls under the category of updates on company fundraising, financing activities, or capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (3991 chars) is substantial enough to be the primary announcement, not just a brief RPA.
2009-04-15 English
Pharming proposes new members for Supervisory Board
Board/Management Information Classification · 99% confidence The document explicitly announces proposals for new members to the Supervisory Board to be voted upon at the upcoming Annual General Meeting (AGM). This content directly relates to the composition and governance structure of the board, which falls under Board/Management Information (MANG). Although it mentions the AGM and the availability of the Annual Report 2008, the primary focus and headline are the proposed management changes. Therefore, MANG is the most appropriate classification.
2009-03-31 English
Pharming confirms Rhucin European MAA filing timeline
Regulatory Filings Classification · 95% confidence The document is a press release from Pharming Group NV announcing the timeline for submitting the Marketing Authorisation Application (MAA) for their drug Rhucin in Europe and preparations for the Biologic License Application (BLA) in the US. It discusses regulatory dialogue (EMEA, FDA), clinical data, and future submission plans. This content relates to regulatory processes and product development updates, but it is not a formal regulatory filing itself (like a 10-K or AR). It is an announcement about regulatory progress. Since it is a specific update concerning regulatory submissions and clinical progress, it fits best under 'Regulatory Filings' (RNS) as a general regulatory announcement, or potentially 'Legal Proceedings Report' (LTR) if the focus was on litigation, but here it is clearly a general operational/regulatory update. Given the options, RNS serves as the best general category for non-standard, specific regulatory news updates that aren't earnings, management changes, or dividend notices. The document length (4358 chars) is moderate, but the content is purely informational about regulatory milestones, not a formal report attachment.
2009-03-31 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.